PNC Financial Services Group
SABS icon

PNC Financial Services Group’s SAB Biotherapeutics SABS Stock Holding History

PNC Financial Services Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1K Buy
10,270
+2,570
+33% +$9.56K ﹤0.01% 3459
2026
Q1 		$29.5K Buy
+7,700
New +$30.7K ﹤0.01% 3506

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PNC Financial Services Group's SABS Position: Q2 2026 in Review

PNC Financial Services Group increased its SAB Biotherapeutics (SABS) stake by 33% in Q2 2026, buying an estimated $9.56K and bringing the position to 10,270 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3459.

PNC Financial Services Group first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • PNC Financial Services Group held 10,270 shares of SAB Biotherapeutics worth $40.1K as of Q2 2026.
  • PNC Financial Services Group bought 2,570 SAB Biotherapeutics shares in Q2 2026, an estimated $9.56K.
  • SAB Biotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3459 holding.
  • PNC Financial Services Group first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.